PRESERVE 1: Phase III, randomized, double-blind study of trilaciclib versus placebo in patients receiving FOLFOXIRI/bevacizumab for metastatic colorectal cancer.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: G1 THERAPEUTICS
- Phase: III
- Execution start: 08/06/2021
- End of execution: 03/05/2025
- IP: ENCARNA GONZALEZ FLORES